Our own experience has shown that integration of [68Ga]PSMA-PET imaging into treatment planning for definitive RT in prostate cancer elevates the detection rate of lymph node spread; moreover, target volumes according to standard guidelines such as by RTOG would not cover affected lymph nodes adequately (up to 35.7% of all lymph nodes) without [68Ga]PSMA-PET imaging [13]. Here, FOLH1 is linked to prostate cancer.